U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

PURPOSE. To describe the clinical studies that led to the FDA approval of rituximab in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with chronic lymphocytic leukemia (CLL). MATERIALS AND METHODS. The results of two multinational, randomized trials in CLL patie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Casak, Sandra J., Lemery, Steven J., Shen, Yuan Li, Rothmann, Mark D., Khandelwal, Aakanksha, Zhao, Hong, Davis, Gina, Jarral, Vaishali, Keegan, Patricia, Pazdur, Richard
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2011
Matèries:
Regulatory Issues: FDA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228054/
https://ncbi.nlm.nih.gov/pubmed/21212432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0306
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars